建立并验证初诊转移性鼻咽癌M1期亚分期以更好预测预后并指导治疗
研究基于三个独立队列(训练集462例、内部前瞻性验证集272例、外部前瞻性验证集243例)分析初诊转移性鼻咽癌的影像学转移特征,将M1期分为M1a、M1b、M1c三个亚期,3年总生存率分别为54.5%至72.8%、34.3%至41.6%、22.6%至23.6%(P<0.001);全身化疗联合根治性局部放疗可能使M1a和M1b患者获益,而非M1c患者;在全身化疗和根治性局部放疗基础上进一步对转移灶行积极治疗未见生存获益,即使对M1a患者亦然(P>0.05)。
要点
- M1期分为M1a(寡转移无肝受累)、M1b(多发转移无肝受累)、M1c(肝受累)。
- 三组3年总生存率分别为54.5%至72.8%、34.3%至41.6%、22.6%至23.6%(P<0.001)。
- 全身化疗联合根治性局部放疗可能使M1a和M1b患者获益,而非M1c患者。
核心结论
- M1期亚分期具有预后价值,可帮助临床医生为初诊转移性鼻咽癌患者选择最合适的治疗。
研究设计与样本
- 研究纳入三个独立队列的初诊转移性鼻咽癌患者:训练集462例、内部前瞻性验证集272例、外部前瞻性验证集243例。
- 基于影像数据定义远处转移的放射学特征,包括转移部位数目、转移病灶数目和转移病灶大小。
- 采用Cox比例风险模型分析上述三个因素及其他潜在预后因素,并整合为新的M1期亚分期。
主要发现
- M1期成功分为三个亚期:M1a为寡转移无肝受累;M1b为多发转移无肝受累;M1c为肝受累,不论转移病灶情况。
- M1a、M1b、M1c的3年总生存率分别为54.5%至72.8%、34.3%至41.6%、22.6%至23.6%(P<0.001)。
- 全身化疗联合根治性局部放疗可能使M1a和M1b患者获益,而非M1c患者。
- 在全身化疗和根治性局部放疗基础上进一步对转移灶行积极治疗未见生存获益,即使对M1a患者亦然(P>0.05)。
关键数值与推荐
- M1a:寡转移无肝受累;M1b:多发转移无肝受累;M1c:肝受累,不论转移病灶情况。
- M1a、M1b、M1c的3年总生存率分别为54.5%至72.8%、34.3%至41.6%、22.6%至23.6%(P<0.001)。
临床怎么用
- M1期亚分期可帮助临床医生为初诊转移性鼻咽癌患者选择最合适的治疗。
- 全身化疗联合根治性局部放疗可能使M1a和M1b患者获益,而非M1c患者。
- 在全身化疗和根治性局部放疗基础上进一步对转移灶行积极治疗未见生存获益,即使对M1a患者亦然(P>0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To better manage patients with de novo metastatic NPC (mNPC) including easily identifying individuals' survival outcomes and accurately choosing the most suitable treatment. MATERIALS AND METHODS: Three independent cohorts of mNPC patients (a training set of n = 462, an internal prospective validation set of n = 272 and an external prospective validation set of n = 243) were studied. The radiological characteristics of distant metastases, including number of metastatic locations, number of metastatic lesions and size of metastatic lesions, were carefully defined based on imaging data. These three factors and other potential prognostic factors were comprehensively analysed and were further integrated into new subdivisions of stage M1 using a Cox proportional hazards model. RESULTS: We successfully subdivided the M1 stage into three categories: M1a, oligo metastasis without liver involvement; M1b, multiple metastases without liver involvement; and M1c, liver involvement irrespective of metastatic lesions. The 3-year overall survival ranged from 54.5% to 72.8%, from 34.3% to 41.6% and from 22.6.0%-23.6% for M1a, M1b and M1c, respectively (P < 0.001). Systemic chemotherapy combined with radical loco-regional radiotherapy may benefit patients in M1a and M1b, not in M1c. Further aggressive treatment of metastatic lesions based on systemic chemotherapy and definitive loco-regional radiotherapy showed no survival benefit, even for patients in M1a (P > 0.05). CONCLUSION: The subdividing of M1 provided promising prognostic value and could aid clinicians in choosing the most suitable treatment for de novo mNPC patients.
引用
- Zou X, You R, Liu H, et al. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. Eur J Cancer. 2017. PMID: 28391025. doi:10.1016/j.ejca.2017.02.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。